| For: | Wishahi M. Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept. World J Hepatol 2024; 16(4): 490-493 [PMID: 38689741 DOI: 10.4254/wjh.v16.i4.490] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v16/i4/490.htm |
| Number | Citing Articles |
| 1 |
Fatemeh Keshavarz, Mohsen Soltanshahi, Malaksima Ayadilord, Faezeh Mortazavi, Mahdi Shabani, Seyed Amir Jalali. Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer. Cancer Cell International 2026; doi: 10.1186/s12935-025-04141-x
|
| 2 |
Matteo Ferro, Felice Crocetto, Letizia Maria Ippolita Jannello, Roberto Contieri, Ugo Giovanni Falagario, Alessandro Veccia, Michele Marchioni, Sabin Octavian Tataru, Biagio Barone, Giuseppe Fallara, Marco Tozzi, Francesco Chierigo, Martina Maggi, Roberto Bianchi, Francesco Pellegrino, Bernardo Maria Cesare Rocco, Vartolomei Mihai Dorin, Daniela Terracciano. Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology. Critical Reviews in Oncology/Hematology 2025; 215: 104862 doi: 10.1016/j.critrevonc.2025.104862
|
